PSTV CEO Marc Hedrick acquires 159,681 shares on RSU vesting

Rhea-AI Filing Summary

Marc H. Hedrick, who is both Chief Executive Officer and a Director of Plus Therapeutics, Inc. (PSTV), had restricted stock units vest on 10/01/2025. The vesting resulted in the acquisition of 159,681 shares of common stock at $0 cost per share because these were RSU settlements, and the filing reports Mr. Hedrick's direct beneficial ownership following the transaction as 180,106 shares in the non-derivative table and 1,756,487 shares in the derivative/underlying summary.

The Form 4 shows these RSUs vest in twelve substantially equal quarterly installments beginning on 10/01/2025, and that the report was submitted by an attorney-in-fact. This is a standard disclosure of insider equity vesting that increases the reporting person’s share holdings and signals management’s equity position without any cash purchase recorded.

Positive

• 159,681 RSUs vested, adding to the CEO's direct holdings and aligning management interests with shareholders
• RSU vesting occurred under a scheduled plan: twelve substantially equal quarterly installments starting on 10/01/2025, indicating a pre-established compensation schedule

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

HEDRICK MARC H

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

4200 MARATHON BOULEVARD, SUITE 200

(Street)

AUSTIN TX 78756

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		M		159,681(2)	A	$0(1)	180,106	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	10/01/2025		M			159,681	(2)	(2)	Common Stock	159,681	$0	1,756,487	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

	Andrew Sims, as attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PLUS THERAPEUTICS (PSTV) report?

The Form 4 reports the vesting and acquisition of 159,681 restricted stock units by Marc H. Hedrick on 10/01/2025.

How many shares does the reporting person beneficially own after the transaction?

The filing shows 180,106 shares in the non-derivative section and a total of 1,756,487 shares referenced in the derivative/underlying section following the reported transactions.

What was the price paid for the shares acquired on vesting?

The RSU settlements are reported at a $0 price per share, reflecting stock issuance on vesting rather than a cash purchase.

When will the RSU grant vest in full?

The explanation states vesting occurs in twelve substantially equal quarterly installments beginning on 10/01/2025.

Who filed the Form 4 on behalf of the reporting person?

The signature block shows the Form 4 was submitted by Andrew Sims, as attorney-in-fact.